H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $34 from $36 and keeps a Buy rating on the shares following the Q4 results.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- RegenXBio’s Strategic Advancements and Financial Stability Highlighted in Analyst Recommendation
- REGENXBIO Earnings Call Highlights Strategic Progress
- Regenxbio price target raised to $24 from $22 at Morgan Stanley
- RegenXBio: Strong Buy Rating Backed by Clinical Progress and Solid Financial Position
- REGENXBIO Reports Progress in Gene Therapy Pipeline